Sen. John Boozman Sells Gilead Sciences, Inc. (NASDAQ:GILD) Stock

Senator John Boozman (R-Arkansas) recently sold shares of Gilead Sciences, Inc. NASDAQ: GILD. In a filing disclosed on May 14th, the Senator disclosed that they had sold between $1,001 and $15,000 in Gilead Sciences stock on April 16th.

Senator John Boozman also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Salesforce NYSE: CRM on 4/22/2025.
• Purchased $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 4/22/2025.
• Purchased $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 4/16/2025.
• Sold $1,001 - $15,000 in shares of Lam Research NASDAQ: LRCX on 4/16/2025.
• Purchased $1,001 - $15,000 in shares of Oracle NYSE: ORCL on 4/16/2025.
• Purchased $1,001 - $15,000 in shares of UnitedHealth Group NYSE: UNH on 4/16/2025.
• Sold $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 4/16/2025.
• Purchased $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 4/15/2025.
• Sold $1,001 - $15,000 in shares of Bank of America NYSE: BAC on 4/15/2025.
• Purchased $1,001 - $15,000 in shares of iShares iBoxx $ High Yield Corporate Bond ETF NYSEARCA: HYG on 4/9/2025.

Gilead Sciences Stock Down 3.0%

Shares of NASDAQ:GILD opened at $98.38 on Thursday. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96. The company has a 50-day moving average price of $106.33 and a 200 day moving average price of $99.50. The company has a market cap of $122.50 billion, a price-to-earnings ratio of 265.89, a PEG ratio of 0.71 and a beta of 0.26.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The firm had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same quarter last year, the firm earned ($1.32) EPS. The firm's revenue for the quarter was down .3% compared to the same quarter last year. As a group, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 3.21%. The ex-dividend date is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Analysts Set New Price Targets

GILD has been the topic of a number of recent analyst reports. Royal Bank of Canada increased their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research report on Wednesday, February 12th. Bank of America increased their price objective on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. DZ Bank raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective on the stock in a research report on Thursday, February 13th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research report on Friday, April 25th. Finally, Morgan Stanley raised their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Nine research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $110.55.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 17,929 shares of the business's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the completion of the sale, the chief financial officer now owns 169,061 shares of the company's stock, valued at $19,977,938.37. The trade was a 9.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last quarter, insiders sold 22,929 shares of company stock valued at $2,644,895. Corporate insiders own 0.27% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GILD. Smallwood Wealth Investment Management LLC acquired a new position in Gilead Sciences during the first quarter valued at $25,000. HHM Wealth Advisors LLC increased its holdings in Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 154 shares in the last quarter. YANKCOM Partnership purchased a new position in Gilead Sciences in the fourth quarter valued at $28,000. Decker Retirement Planning Inc. purchased a new position in Gilead Sciences in the fourth quarter valued at $29,000. Finally, Goodman Advisory Group LLC purchased a new position in Gilead Sciences in the first quarter valued at $29,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

About Senator Boozman

John Boozman (Republican Party) is a member of the U.S. Senate from Arkansas. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Boozman (Republican Party) ran for re-election to the U.S. Senate to represent Arkansas. He won in the general election on November 8, 2022. Boozman won re-election in 2016. He faced Democrat Conner Eldridge, Libertarian Frank Gilbert, and write-in candidate Jason Tate in the general election. Arkansas' U.S. Senate race was rated as safely Republican in 2016. Boozman began his political career in the U.S. House. He won a special election in 2001 and served in that position until his election to the Senate in 2010. Prior to his political career, Boozman worked as an optometrist. As of a 2014 analysis of multiple outside rankings, Boozman is an average Republican member of Congress, meaning he will vote with the Republican Party on the majority of bills. Below is an abbreviated outline of Boozman's academic, professional, and political career: 2011-Present: U.S. Senator from Arkansas 2001-2011: U.S. Representative from Arkansas 1977: Graduated from Southern College of Optometry

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.